Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Published Erratum
. 2018 Oct 1;4(10):1439.
doi: 10.1001/jamaoncol.2018.4091.

Missing Conflict of Interest Disclosure

No authors listed
Published Erratum

Missing Conflict of Interest Disclosure

No authors listed. JAMA Oncol. .
No abstract available

PubMed Disclaimer

Erratum for

Comment in

References

    1. Hernandez I, Prasad V, Gellad WF. Total costs of chimeric antigen receptor T-cell immunotherapy [published online April 26, 2018]. JAMA Oncol. 2018;4(7):994-996. doi:10.1001/jamaoncol.2018.0977 - DOI - PMC - PubMed
    1. Marquart J, Chen EY, Prasad V. Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology [published online April 17, 2018]. JAMA Oncol. doi:10.1001/jamaoncol.2018.1660 - DOI - PMC - PubMed
    1. Mailankody S, Prasad V. Overall survival vs disease-specific survival—reply. JAMA Oncol. 2018;4(4):586-587. doi:10.1001/jamaoncol.2017.3865 - DOI - PubMed
    1. Prasad V, Kaestner V, Mailankody S. Cancer drugs approved based on biomarkers and not tumor type—FDA approval of pembrolizumab for mismatch repair-deficient solid cancers. JAMA Oncol. 2018;4(2):157-158. doi:10.1001/jamaoncol.2017.4182 - DOI - PubMed
    1. Gyawali B, Prasad V. Pemetrexed in nonsquamous non–small-cell lung cancer: the billion dollar subgroup analysis. JAMA Oncol. 2018;4(1):17-18. doi:10.1001/jamaoncol.2017.1944 - DOI - PubMed

Publication types